Publications
Below you can find a list of our published research.
Below you can find a list of our published research.
112 results
Cited 1 times since 2022 (0.6 per year) source: EuropePMC
Frontiers in cardiovascular medicine, Volume 9, 13 2 2022, Pages 969766 Systemic thrombolysis in the management of pump thrombosis in patients with left ventricular assist devices. Kortekaas KA, den Exter PL, Beeres SLMA, Palmen M, Jukema JW, Huisman MV, Tops LF
Left ventricular assist device (LVAD) implantation as destination therapy (DT) is a valuable treatment option in patients with end-stage heart failure ineligible for heart transplant. However, this therapy can be complicated by life-threatening pump thrombosis (PT). This case series reports our single-center experience with a structured systemic thrombolysis protocol in case of PT. Consecutive patients undergoing DT LVAD (HVAD, Medtronic, Framingham, MA) implantation between 2010 and April 2021... Abstract
Cited 2 times since 2022 (1.2 per year) source: EuropePMC
BMJ open, Volume 12, Issue 9, 19 3 2022, Pages e061337 Prevention of vasoplegia with CytoSorb in heart failure patients undergoing cardiac surgery (CytoSorb-HF trial): protocol for a randomised controlled trial. Papazisi O, Bruggemans EF, Berendsen RR, Hugo JDV, Lindeman JHN, Beeres SLMA, Arbous MS, van den Hout WB, Mertens BJA, Ince C, Klautz RJM, Palmen M
Introduction: Vasoplegia is a common complication after cardiac surgery and is associated with poor prognosis. It is characterised by refractory hypotension despite normal or even increased cardiac output. The pathophysiology is complex and includes the systemic inflammatory response caused by cardiopulmonary bypass (CPB) and surgical trauma. Patients with end-stage heart failure (HF) are at increased risk for developing vasoplegia. The CytoSorb adsorber is a relatively new haemoadsorption devic... Abstract
Cited 2 times since 2022 (1.2 per year) source: EuropePMC
Interactive cardiovascular and thoracic surgery, Volume 35, Issue 4, 1 1 2022, Pages ivac108 Robotic coronary revascularization in Europe, state of art and future of EACTS-endorsed Robotic Cardiothoracic Surgery Taskforce. Pettinari M, Gianoli M, Palmen M, Cerny S, Onan B, Singh S, Segers P, Bolcal C, Alhan C, Navarra E, De Praetere H, Vojacek J, Cebotaru T, Modi P, Doguet F, Franke U, Ouda A, Melly L, Malapert G, Labrousse L, Agnino A, Philipsen T, Jansens JL, Folliguet T, Pereda D, Musumeci F, Suwalski P, Cathenis K, Van Praet F, Bonatti J, Oosterlinck W, European Robotic CardioThoracic Surgeons (ERCTS)
The international journal of cardiovascular imaging, Volume 38, Issue 12, 19 3 2022, Pages 2771-2779 Left ventricular assist device and pump thrombosis: the importance of the inflow cannula position. Kortekaas KA, de Graaf MA, Palmen M, Braun J, Mertens BJA, Tops LF, Beeres SLMA
Pump thrombosis is a devastating complication after left ventricular assist device implantation. This study aims to elucidate the relation between left ventricular assist device implantation angle and risk of pump thrombosis. Between November 2010 and March 2020, 53 left ventricular assist device-patients underwent a computed tomography scan. Using a 3-dimensional multiplanar reformation the left ventricular axis was reconstructed to measure the implantation angle of the inflow cannula. All pati... Abstract
Cited 2 times since 2022 (1.1 per year) source: EuropePMC
Journal of cardiovascular development and disease, Volume 9, Issue 7, 18 3 2022, Pages 230 Left Atrial Remodeling after Mitral Valve Repair for Primary Mitral Regurgitation: Evolution over Time and Prognostic Significance. Stassen J, van Wijngaarden AL, Wu HW, Palmen M, Tomsic A, Delgado V, Bax JJ, Marsan NA
Left atrial (LA) dilatation is associated with worse outcomes in primary mitral regurgitation (MR). However, the effects of mitral valve repair on LA size and its prognostic implications are not well known. In the current study, LA volume index (LAVi) and LA reservoir strain (LASr) were evaluated immediately before and after surgery, and during long-term follow-up in 226 patients undergoing mitral valve repair for primary MR (age 62 ± 13 years, 66% male). Mean LAVi was reduced significantly afte... Abstract
Interactive cardiovascular and thoracic surgery, Volume 35, Issue 2, 1 1 2022, Pages ivac171 From macro-effective to microinvasive: what is the right balance? Tomšič A, Klautz RJM, Palmen M
Artificial organs, Volume 46, Issue 8, 31 5 2022, Pages 1709-1710 Unexpected negative results for CytoSorb during left ventricular assist device implantation: interpret with caution. Papazisi O, Arabkhani B, Palmen M
Cited 1 times since 2022 (0.5 per year) source: EuropePMC
Journal of cardiothoracic surgery, Volume 17, Issue 1, 7 1 2022, Pages 108 Accuracy of point-of-care coagulation testing during cardiopulmonary bypass in a patient post COVID-19 infection. Grewal N, Yousef D, Palmen M, Klautz R, Eikenboom J, Wink J
Introduction: Extracorporeal circulation (ECC) in cardiac surgery is performed under systemic heparinization. Adequacy of heparin therapy and anticoagulation during ECC is assessed by activated clotting time (ACT), although there are concerns regarding the reliability of this measure. The ACT can be affected by factors other than heparin anticoagulation. A novel factor that should be considered is the influence of a COVID-19 infection. More than half of the hospitalized COVID-19 patients develop... Abstract
The New England journal of medicine, Volume 386, Issue 19, 1 1 2022, Pages 1862 Tricuspid Repair in Patients with Degenerative Mitral Regurgitation. Tomšič A, Palmen M, Klautz RJM
Cited 1 times since 2022 (0.5 per year) source: EuropePMC
Frontiers in cardiovascular medicine, Volume 9, 7 1 2022, Pages 870390 Corrigendum: Robotic Cardiac Surgery in Europe: Status 2020. Cerny S, Oosterlinck W, Onan B, Singh S, Segers P, Bolcal C, Alhan C, Navarra E, Pettinari M, Van Praet F, De Praetere H, Vojacek J, Cebotaru T, Modi P, Doguet F, Franke U, Ouda A, Melly L, Malapert G, Labrousse L, Gianoli M, Agnino A, Philipsen T, Jansens JL, Folliguet T, Palmen M, Pereda D, Musumeci F, Suwalski P, Cathenis K, Van den Eynde J, Bonatti J
[This corrects the article DOI: 10.3389/fcvm.2021.827515.]. Abstract
Cited 17 times since 2022 (7.3 per year) source: EuropePMC
Frontiers in cardiovascular medicine, Volume 8, 20 3 2022, Pages 827515 Robotic Cardiac Surgery in Europe: Status 2020. Cerny S, Oosterlinck W, Onan B, Singh S, Segers P, Bolcal C, Alhan C, Navarra E, Pettinari M, Van Praet F, De Praetere H, Vojacek J, Cebotaru T, Modi P, Doguet F, Franke U, Ouda A, Melly L, Malapert G, Labrousse L, Gianoli M, Agnino A, Philipsen T, Jansens JL, Folliguet T, Palmen M, Pereda D, Musumeci F, Suwalski P, Cathenis K, Van den Eynde J, Bonatti J
Background: European surgeons were the first worldwide to use robotic techniques in cardiac surgery and major steps in procedure development were taken in Europe. After a hype in the early 2000s case numbers decreased but due to technological improvements renewed interest can be noted. We assessed the current activities and outcomes in robotically assisted cardiac surgery on the European continent. Methods: Data were collected in an international anonymized registry of 26 European centers with a... Abstract
Cited 8 times since 2022 (3.4 per year) source: EuropePMC
JACC. Cardiovascular imaging, Volume 15, Issue 6, 12 2 2022, Pages 961-970 Prognostic Impact of Extra-Mitral Valve Cardiac Involvement in Patients With Primary Mitral Regurgitation. van Wijngaarden AL, Mantegazza V, Hiemstra YL, Volpato V, van der Bijl P, Pepi M, Palmen M, Delgado V, Ajmone Marsan N, Tamborini G, Bax JJ
Background: In patients with severe primary mitral regurgitation (MR), the indication for surgery is currently based on the presence of symptoms, left ventricular dilatation and dysfunction, atrial fibrillation, and pulmonary hypertension. Objectives: The aim of this study was to evaluate the prognostic impact of the presence of extra-mitral valve cardiac involvement (including known risk factors but also severe left atrial [LA] dilatation and right ventricular [RV] dysfunction) in a large multi... Abstract
Multimedia manual of cardiothoracic surgery : MMCTS, Volume 2021, 25 4 2021 Patch repair in infective native mitral valve endocarditis. Velders BJJ, Tomšič A, Klautz RJM, Palmen M
Infective native mitral valve endocarditis occurs rarely. Mitral valve repair, although surgically challenging, is favored over replacement in the latest European and American guidelines. In this video tutorial, patch repair of the posterior mitral valve leaflet is performed in a 61-year-old patient with endocarditis caused by Streptococcus agalactiae. Abstract
JTCVS open, Volume 8, 5 1 2021, Pages 300 Reply from authors: Many roads lead to Rome. Wijngaarden AL, Tomšič A, Marsan NA, Palmen M
Alcohol and alcoholism (Oxford, Oxfordshire), Volume 56, Issue 5, 1 1 2021, Pages 630-631 Response to Letter by Benson et al. on 'Hangover and the Effects of L-Cysteine'. Eriksson CJP, Metsälä M, Möykkynen T, Mäkisalo H, Kärkkäinen O, Palmén M, Salminen JE, Kauhanen J
Cited 2 times since 2021 (0.7 per year) source: EuropePMC
Journal of cardiovascular development and disease, Volume 8, Issue 7, 8 2 2021, Pages 79 Superimposed Tissue Formation in Human Aortic Valve Disease: Differences between Regurgitant and Stenotic Valves. Kruithof BPT, van Wijngaarden AL, Mousavi Gourabi B, Hjortnaes J, Palmen M, Ajmone Marsan N
The formation of superimposed tissue (SIT), a layer on top of the original valve leaflet, has been described in patients with mitral regurgitation as a major contributor to valve thickening and possibly as a result of increased mechanical stresses. However, little is known whether SIT formation also occurs in aortic valve disease. We therefore performed histological analyses to assess SIT formation in aortic valve leaflets (n = 31) from patients with aortic stenosis (n = 17) or aortic regurgitat... Abstract
Cited 6 times since 2021 (1.9 per year) source: EuropePMC
Interactive cardiovascular and thoracic surgery, Volume 32, Issue 4, 1 1 2021, Pages 506-514 Evolution from mitral annular dysfunction to severe mitral regurgitation in Barlow's disease. Hiemstra YL, Tomsic A, Gripari P, van Wijngaarden AL, van der Pas SL, Palmen M, Klautz RJM, Pepi M, Bax JJ, Delgado V, Marsan NA
Objectives: Barlow's disease (BD) is characterized by thick, redundant mitral valve (MV) leaflets, which can lead to prolapse and significant mitral regurgitation (MR). MV annular abnormalities are also commonly observed and increasingly recognized as possible primary pathology, with leaflet thickening being secondary to increased stress on the MV apparatus. To provide more insights into this hypothesis, the evolution of MV abnormalities over time in patients with BD was assessed. Methods:... Abstract
Cited 3 times since 2021 (0.9 per year) source: EuropePMC
The Journal of thoracic and cardiovascular surgery, Volume 164, Issue 5, 23 4 2021, Pages 1488-1497.e3 Mitral valve repair for isolated posterior mitral valve leaflet prolapse: The effect of respect and resect techniques on left ventricular function. van Wijngaarden AL, Tomšič A, Mertens BJA, Fortuni F, Delgado V, Bax JJ, Klautz RJM, Marsan NA, Palmen M
Objective: Posterior mitral valve leaflet prolapse repair can be performed by leaflet resection or chordal replacement techniques. The impact of these techniques on left ventricular function remains a topic of debate, considering the presumed better preservation of mitral-ventricular continuity when leaflet resection is avoided. We explored the effect of different posterior mitral valve leaflet repair techniques on postoperative left ventricular function. Methods: In total, 125 patients were inc... Abstract
Cited 5 times since 2020 (1.4 per year) source: EuropePMC
Cells, Volume 9, Issue 11, 4 1 2020, Pages E2412 Cardiac and Vascular α<sub>1</sub>-Adrenoceptors in Congestive Heart Failure: A Systematic Review. Kaykı-Mutlu G, Papazisi O, Palmen M, Danser AHJ, Michel MC, Arioglu-Inan E
As heart failure (HF) is a devastating health problem worldwide, a better understanding and the development of more effective therapeutic approaches are required. HF is characterized by sympathetic system activation which stimulates α- and β-adrenoceptors (ARs). The exposure of the cardiovascular system to the increased locally released and circulating levels of catecholamines leads to a well-described downregulation and desensitization of β-ARs. However, information on the role of α-AR is limit... Abstract
Cited 9 times since 2020 (2.5 per year) source: EuropePMC
Cardiovascular drugs and therapy, Volume 36, Issue 4, 21 3 2020, Pages 739-748 The Use of Angiotensin II for the Treatment of Post-cardiopulmonary Bypass Vasoplegia. Papazisi O, Palmen M, Danser AHJ
Purpose: Vasoplegia is a common complication after cardiac surgery and is related to the use of cardiopulmonary bypass (CPB). Despite its association with increased morbidity and mortality, no consensus exists in terms of its treatment. In December 2017, angiotensin II (AII) was approved by the Food and Drug Administration (FDA) for use in vasodilatory shock; however, except for the ATHOS-3 trial, its use in vasoplegic patients that underwent cardiac surgery on CPB has mainly been reported in ca... Abstract